• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prognostic factors in patients with advanced stage prostate cancer.

作者信息

Emrich L J, Priore R L, Murphy G P, Brady M F

出版信息

Cancer Res. 1985 Oct;45(10):5173-9.

PMID:4027993
Abstract

The relationships of 13 potential prognostic factors to objective response to treatment and survival time were investigated, using data gathered on 1,020 patients with advanced stage prostate cancer who have participated in the clinical trials of the National Prostatic Cancer Project. Multivariate statistical analyses revealed that previous hormone response status, analgesics, pain, elevated acid phosphatase, and anemia were the important, independent prognostic factors for objective response to treatment. For survival time, the significant prognostic factors were previous hormone response status, anorexia, elevated acid phosphatase, pain, elevated alkaline phosphatase, obstructive symptoms, tumor grade, performance status, anemia, and age at diagnosis. It is recommended that future treatment protocols for advanced stage prostate cancer take into account heterogeneity of the treatment groups with respect to these factors, either through the design of the protocol, or at the time of analysis.

摘要

相似文献

1
Prognostic factors in patients with advanced stage prostate cancer.
Cancer Res. 1985 Oct;45(10):5173-9.
2
Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.前列腺特异性抗原/前列腺酸性磷酸酶比值是IV期前列腺癌患者的重要预后因素。
Urology. 2007 Oct;70(4):702-5. doi: 10.1016/j.urology.2007.05.019.
3
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.血清白细胞介素6作为前列腺癌患者的预后因素。
Clin Cancer Res. 2000 Jul;6(7):2702-6.
4
[Multivariate analysis of prognostic factors in patients with prostatic cancer].[前列腺癌患者预后因素的多变量分析]
Hinyokika Kiyo. 1991 Dec;37(12):1663-8.
5
[Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].[前列腺腺癌在诊断时发生转移的演变及预后因素]
Actas Urol Esp. 1997 Sep;21(8):724-36.
6
Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.转移性(D2期)前列腺癌患者的预后因素:来自斯堪的纳维亚前列腺癌研究组-2的经验
J Urol. 1997 Jul;158(1):164-70. doi: 10.1097/00005392-199707000-00052.
7
[Prognostic factors in stage D2 prostate cancer: results of univariate and multivariate analyses].
Hinyokika Kiyo. 1996 Apr;42(4):269-74.
8
Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.血清胃泌素释放肽前体(31-98)水平升高是转移性前列腺癌激素治疗后反应持续时间短的一个预测指标。
Prostate. 2003 Sep 1;56(4):305-12. doi: 10.1002/pros.10260.
9
[Clinical assessments on pre-treatment prognostic factors in 138 patients with advanced prostatic carcinoma (stage D2)].[138例晚期前列腺癌(D2期)患者治疗前预后因素的临床评估]
Hinyokika Kiyo. 1993 Feb;39(2):131-4.
10
PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.前列腺特异性抗原(PSA)的变化:全雄激素阻断治疗晚期前列腺癌过程中的一个预后因素。来自比利时一项对546例患者的多中心研究的数据。
Acta Urol Belg. 1997 Oct;65(3):63-71.

引用本文的文献

1
Prognostic Value of Preoperative Hemoglobin in Patients Undergoing Radical Prostatectomy for Localized Prostate Cancer.术前血红蛋白对局限性前列腺癌行根治性前列腺切除术患者的预后价值
Cancers (Basel). 2025 Aug 12;17(16):2633. doi: 10.3390/cancers17162633.
2
The Prediction of Survival Outcome and Prognosis Factor in Association with Comorbidity Status in Patients with Colorectal Cancer: A Research-Based Study.结直肠癌患者生存结局的预测及与合并症状态相关的预后因素:一项基于研究的研究
Healthcare (Basel). 2022 Sep 5;10(9):1693. doi: 10.3390/healthcare10091693.
3
Prognostic Factors Influencing Survival Rate of Patients Operated for Prostate-Related Metastatic Spinal Cord Compression (MSCC).
影响因前列腺相关转移性脊髓压迫症(MSCC)接受手术患者生存率的预后因素。
Indian J Surg Oncol. 2020 Sep;11(3):498-508. doi: 10.1007/s13193-020-01155-x. Epub 2020 Jul 15.
4
Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer.利用医疗索赔数据库为接受亮丙瑞林治疗的激素敏感性前列腺癌患者开发人群疾病进展模型。
PLoS One. 2020 Mar 24;15(3):e0230571. doi: 10.1371/journal.pone.0230571. eCollection 2020.
5
Prognostic value of serum alkaline phosphatase in spinal metastatic disease.血清碱性磷酸酶在脊柱转移疾病中的预后价值。
Br J Cancer. 2019 Mar;120(6):640-646. doi: 10.1038/s41416-019-0407-8. Epub 2019 Feb 22.
6
Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.去势抵抗性前列腺癌六基因预后模型的基因变异与生存的关联
Prostate. 2019 Jan;79(1):73-80. doi: 10.1002/pros.23712. Epub 2018 Aug 23.
7
A systematic review of the impact of pain on overall survival in patients with cancer.一项关于疼痛对癌症患者总生存期影响的系统评价。
Support Care Cancer. 2017 May;25(5):1687-1698. doi: 10.1007/s00520-017-3614-y. Epub 2017 Feb 11.
8
Radium-223 and concomitant therapies: prospects and prudence.镭-223与联合疗法:前景与审慎考量
Transl Androl Urol. 2016 Dec;5(6):968-970. doi: 10.21037/tau.2016.11.04.
9
Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy.接受亮丙瑞林长效注射剂作为雄激素剥夺治疗的晚期前列腺癌患者生化进展的预测性临床指标。
PLoS One. 2014 Aug 14;9(8):e105091. doi: 10.1371/journal.pone.0105091. eCollection 2014.
10
Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.根治性前列腺切除术后接受雄激素剥夺治疗的生化复发患者的生存分析:去势抵抗的影响因素。
Can Urol Assoc J. 2014 May;8(5-6):E333-41. doi: 10.5489/cuaj.1665.